[go: up one dir, main page]

BR0311801A - Composição de imidazol, método para produção do mesmo, composição farmacêutica, embalagem comercial, método para a profilaxia ou tratamento de doenças, método para erradicar helicobacter pylori de um animal infectado com helicobacter pylori, e, uso de um composto - Google Patents

Composição de imidazol, método para produção do mesmo, composição farmacêutica, embalagem comercial, método para a profilaxia ou tratamento de doenças, método para erradicar helicobacter pylori de um animal infectado com helicobacter pylori, e, uso de um composto

Info

Publication number
BR0311801A
BR0311801A BR0311801-0A BR0311801A BR0311801A BR 0311801 A BR0311801 A BR 0311801A BR 0311801 A BR0311801 A BR 0311801A BR 0311801 A BR0311801 A BR 0311801A
Authority
BR
Brazil
Prior art keywords
helicobacter pylori
compound
treatment
composition
pharmaceutical composition
Prior art date
Application number
BR0311801-0A
Other languages
English (en)
Inventor
Keiji Kamiyama
Hiroshi Banno
Fumihiko Sato
Original Assignee
Takeda Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical
Publication of BR0311801A publication Critical patent/BR0311801A/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/90Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

"COMPOSTO DE IMIDAZOL, MéTODO PARA PRODUçãO DO MESMO, COMPOSIçãO FARMACêUTICA, EMBALAGEM COMERCIAL, MéTODO PARA A PROFILAXIA OU TRATAMENTO DE DOENçAS, MéTODO PARA ERRADICAR HELICOBACTER PYLORI DE UM ANIMAL INFECTADO COM HELICOBACTER PYLORI, E, USO DE UM COMPOSTO". Um composto de imidazol representado pela fórmula (I) um sal do mesmo e um composto da fórmula (V) que é um dos intermediários do mesmo, sendo que cada símbolo é como definido na presente descrição. O composto da presente invenção apresenta uma atividade superior anti-úlcera, uma ação inibidora de secreção de ácido gástrico, uma ação protetora de mucosa, uma ação anti-Helicobacter pylori action e análogos. Como apresenta baixa toxicidade, o composto é útil como um produto farmacêutico.
BR0311801-0A 2002-06-14 2003-06-13 Composição de imidazol, método para produção do mesmo, composição farmacêutica, embalagem comercial, método para a profilaxia ou tratamento de doenças, método para erradicar helicobacter pylori de um animal infectado com helicobacter pylori, e, uso de um composto BR0311801A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2002175086 2002-06-14
JP2003041085 2003-02-19
PCT/JP2003/007546 WO2003105845A1 (en) 2002-06-14 2003-06-13 Prodrugs of imidazole derivatives, for use as proton pump inhibitors in the treatment of e.g. peptic ulcers

Publications (1)

Publication Number Publication Date
BR0311801A true BR0311801A (pt) 2005-04-12

Family

ID=29738411

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0311801-0A BR0311801A (pt) 2002-06-14 2003-06-13 Composição de imidazol, método para produção do mesmo, composição farmacêutica, embalagem comercial, método para a profilaxia ou tratamento de doenças, método para erradicar helicobacter pylori de um animal infectado com helicobacter pylori, e, uso de um composto

Country Status (19)

Country Link
US (2) US7410981B2 (pt)
EP (2) EP1513527B1 (pt)
JP (1) JPWO2003106429A1 (pt)
KR (1) KR20050009751A (pt)
CN (1) CN1678315A (pt)
AR (1) AR040221A1 (pt)
AT (1) ATE437642T1 (pt)
AU (2) AU2003242390A1 (pt)
BR (1) BR0311801A (pt)
CA (2) CA2489470A1 (pt)
DE (1) DE60328603D1 (pt)
IL (1) IL165562A0 (pt)
MX (1) MXPA04012396A (pt)
NO (1) NO20050141L (pt)
OA (1) OA12867A (pt)
PE (1) PE20040563A1 (pt)
PL (1) PL373085A1 (pt)
TW (1) TW200307544A (pt)
WO (2) WO2003106429A1 (pt)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE602004022337D1 (de) 2004-04-28 2009-09-10 Hetero Drugs Ltd Verfahren zur herstellung von pyridinylmethyl-1h-benzimidazolverbindungen in enantiomerenangereicherter form oder als einzelne enantiomere
WO2006090845A1 (ja) 2005-02-25 2006-08-31 Takeda Pharmaceutical Company Limited 顆粒の製造方法
KR101148399B1 (ko) * 2005-06-22 2012-05-23 일양약품주식회사 항궤양제 및 점막보호제를 함유하는 경구용 위장질환치료용 약제 조성물
US20100317689A1 (en) * 2006-09-19 2010-12-16 Garst Michael E Prodrugs of proton pump inhibitors including the 1h-imidazo[4,5-b] pyridine moiety
MX2009004475A (es) 2006-10-27 2009-08-12 Univ Missouri Composiciones que comprenden agentes acido labiles que inhiben la bomba de protones, por lo menos otro agente farmaceuticamente activo y metodos de uso de las misma.
US8247440B2 (en) 2008-02-20 2012-08-21 Curators Of The University Of Missouri Composition comprising omeprazole, lansoprazole and at least one buffering agent
WO2011056652A1 (en) 2009-10-28 2011-05-12 Newlink Genetics Imidazole derivatives as ido inhibitors
US8916563B2 (en) 2010-07-16 2014-12-23 The Trustees Of Columbia University In The City Of New York Aldose reductase inhibitors and uses thereof
WO2016172436A1 (en) * 2015-04-23 2016-10-27 Temple University-Of The Commonwealth System Of Higher Education Polycationic amphiphiles and polymers thereof as antimicrobial agents and methods using same
EP3757107B1 (en) * 2016-06-21 2023-10-25 The Trustees of Columbia University in the City of New York 4-oxo-3,4-dihydrothieno[3,4-d]pyridazine compounds as aldose reductase inhibitors and methods of use thereof
WO2018081347A1 (en) 2016-10-26 2018-05-03 Temple University-Of The Commonwealth System Of Higher Education Polycationic amphiphiles as antimicrobial agents and methods using same
ES2983586T3 (es) 2017-07-28 2024-10-23 Applied Therapeutics Inc Composiciones y procedimientos para el tratamiento de la galactosemia
CN113840825A (zh) 2019-04-01 2021-12-24 应用治疗公司 醛糖还原酶抑制剂
JP2022531466A (ja) 2019-05-07 2022-07-06 ユニバーシティ オブ マイアミ 遺伝性ニューロパチーおよび関連障害の処置および検出
PT4148050T (pt) * 2020-06-17 2025-01-29 Ildong Pharmaceutical Co Ltd Novo inibidor da secreção ácida e sua utilização
IT202200001022A1 (it) * 2022-01-21 2023-07-21 Exo Lab Italia Composti farmaceutici ibridi ottenuti mediante coniugazione di un inibitore delle pompe protoniche e un inibitore delle anidrasi carboniche
CN120590773B (zh) * 2025-08-06 2025-12-26 广州仕天材料科技有限公司 一种增强型聚碳酸酯和制备方法及在汽车照明系统中的应用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE416649B (sv) * 1974-05-16 1981-01-26 Haessle Ab Forfarande for framstellning av foreningar som paverkar magsyrasekretionen
SE8300736D0 (sv) * 1983-02-11 1983-02-11 Haessle Ab Novel pharmacologically active compounds
KR890000387B1 (ko) * 1984-09-24 1989-03-16 디 엎존 캄파니 2-(피리딜알켄술 피닐)벤즈 이미드아졸류의 n-치환 유도체의 제조방법
IL76839A (en) * 1984-10-31 1988-08-31 Byk Gulden Lomberg Chem Fab Picoline derivatives,processes for the preparation thereof and pharmaceutical compositions containing the same
SE8505112D0 (sv) * 1985-10-29 1985-10-29 Haessle Ab Novel pharmacological compounds
US4965269A (en) * 1989-12-20 1990-10-23 Ab Hassle Therapeutically active chloro substituted benzimidazoles
US5614549A (en) * 1992-08-21 1997-03-25 Enzon, Inc. High molecular weight polymer-based prodrugs
US6093734A (en) * 1998-08-10 2000-07-25 Partnership Of Michael E. Garst, George Sachs, And Jai Moo Shin Prodrugs of proton pump inhibitors
KR20020004995A (ko) * 1999-04-09 2002-01-16 스타르크, 카르크 트롬빈 억제제의 프로드럭
US6765019B1 (en) * 1999-05-06 2004-07-20 University Of Kentucky Research Foundation Permeable, water soluble, non-irritating prodrugs of chemotherapeutic agents with oxaalkanoic acids
DE60144123D1 (de) * 2000-07-07 2011-04-07 Spectrum Pharmaceuticals Inc Verfahren zur Behandlung von Arzneimittelinduzierter peripherer Neuropathie und verwandten Krankheitsformen
AU2001294228A1 (en) 2000-10-12 2002-04-22 Takeda Chemical Industries Ltd. Benzimidazole compounds, process for producing the same and use thereof
KR20030033007A (ko) * 2001-05-31 2003-04-26 코울터 파머수티컬, 인코포레이티드 세포독소, 약물전구체, 링커 및 이에 유용한 안정화제
EP1437352A4 (en) 2001-09-25 2004-12-08 Takeda Chemical Industries Ltd BENZIMIDAZOLE COMPOUND, METHOD FOR THE PRODUCTION AND USE THEREOF

Also Published As

Publication number Publication date
WO2003105845A1 (en) 2003-12-24
EP1513527A1 (en) 2005-03-16
TW200307544A (en) 2003-12-16
IL165562A0 (en) 2006-01-15
OA12867A (en) 2006-09-15
AU2003242388A1 (en) 2003-12-31
EP1514870A1 (en) 2005-03-16
US7410981B2 (en) 2008-08-12
AR040221A1 (es) 2005-03-16
AU2003242390A1 (en) 2003-12-31
DE60328603D1 (de) 2009-09-10
CA2489470A1 (en) 2003-12-24
NO20050141L (no) 2005-01-27
NO20050141D0 (no) 2005-01-11
PL373085A1 (en) 2005-08-08
WO2003106429A1 (ja) 2003-12-24
EP1514870A4 (en) 2006-08-23
CN1678315A (zh) 2005-10-05
JPWO2003106429A1 (ja) 2005-10-13
US20050222210A1 (en) 2005-10-06
CA2489361A1 (en) 2003-12-24
EP1513527B1 (en) 2009-07-29
MXPA04012396A (es) 2005-06-17
US20060293371A1 (en) 2006-12-28
ATE437642T1 (de) 2009-08-15
KR20050009751A (ko) 2005-01-25
PE20040563A1 (es) 2004-10-21

Similar Documents

Publication Publication Date Title
BR0311801A (pt) Composição de imidazol, método para produção do mesmo, composição farmacêutica, embalagem comercial, método para a profilaxia ou tratamento de doenças, método para erradicar helicobacter pylori de um animal infectado com helicobacter pylori, e, uso de um composto
BRPI0409109A (pt) novos compostos
MX2022010795A (es) Hidrato cristalino de un compuesto inhibidor de jak.
BRPI0518222A (pt) composto, processo para a sua manufatura, composições farmacêuticas que os compreendem, método para o tratamento e/ou prevenção de enfermidades que estão associadas com a modulação de receptores de h3 e utilização dos mesmos
BRPI0413490A (pt) novos compostos
BR0311494A (pt) Novos indóis substituìdos
BR112013010310A2 (pt) inibidores de acetil-coa carboxilase de lactama n1/n2
BRPI0408369A (pt) derivados de indol úteis para o tratamento de doenças
BR0211122A (pt) Composto, métodos para o tratamento ou prevenção de doenças e para fabricar um composto, intermediário, e, uso de um composto ou sal
BRPI0417687A (pt) derivados de benzenossulfonilamino-piridin-2-ila e compostos relacionados como inibidores de 11-beta-hidroxiesteróide desidrogenase tipo 1 (11-beta-hsd-1) para o tratamento de diabetes e obesidade
BR0010555A (pt) Inibidores de neuraminidases
EE200300324A (et) Asendatud alküülamiini derivaadid ja nende kasutamismeetodid
BR0211119A (pt) Composto, método de tratar um paciente que tenha, ou de prevenir um paciente de pegar, uma doença ou condição, uso de um composto, e, método para fabricar um composto
EA200500286A1 (ru) Новые изотиазольные и изоксазольные соединения в качестве ингибиторов трансформирующего фактора роста (тфр)
BRPI0715746B8 (pt) composto ou sal farmaceuticamente aceitável do mesmo e composição farmacêutica os compreendendo
TNSN04203A1 (en) Benzoxazinone-derived compounds, their preparation and use as medicaments
BRPI0514448A (pt) derivados do ácido bifenil-oxiacético para uso no tratamento de doenças respiratórias
BRPI0416287A (pt) compostos, processo para a manufatura dos mesmos, composições farmacêuticas que os compreendem, método para o tratamento e/ou prevenção de enfermidades que são moduladas por inibidores de accß e sua utilização
NZ593996A (en) Naphthyridine-carboxamide and isoquinoline-carboxamide derivatives for treating osteoporosis
BR0307801A (pt) Processo para a fabricação de derivados de ácido mevalÈnico inibidores da hmg-coa reductase
BR0307588A (pt) Composto, inibidor de gsk-3, composição farmacêutica, e, agente terapêutico ou preventivo para uma doença
EA200600878A1 (ru) Производные феноксиуксусных кислот, применимые в качестве двойных агонистов активируемого пероксисомным пролифератором рецептора ( ppar )
BR0314352A (pt) Indóis 2,7-substituìdos e seu uso como moduladores de 5-ht6
MY147951A (en) Crystalline potassium salt of lipoxin a? analogs
BRPI0507120A (pt) compostos, processo para a manufatura dos mesmos, composições farmacêuticas que os compreendem, método para o tratamento e/ou profilaxia de enfermidades que estão associadas com a modulação de receptores de cb1 e sua utilização

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 5A,6A E 7A ANUIDADES

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2064 DE 27/07/2010.